About OcuTerra Therapeutics
OcuTerra Therapeutics is a private company based in Boston, Massachusetts. It has reported $57,151,405 raised in three offerings on Form D since September 2019. Its chief executive is Kerrie Brady.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 14, 2023 | Dec 22, 2023amended Feb 22, 2024 | $25,625,440fully sold | 279 | $91,847 | Equity, Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 27, 2021 | May 11, 2021amended Aug 24, 2021 | $31,525,965of $50.0M target | 226 | $139K | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Not yet | Sep 26, 2019 | $0of $1.5M target | 0 | — | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, three offerings | $57,151,405 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on OcuTerra Therapeutics's Form D filed Feb 22, 2024.
Earlier filings also listed Robert Dempsey (director, last listed Aug 2021), David Edwards (chief development operations officer, last listed Aug 2021), Brent Saunders (director, last listed Aug 2021), Michael Turner (director, last listed Sep 2019) and Joseph Pignato (director, last listed Sep 2019).